ALXN2030

Phase 2Small molecule

AstraZeneca

ALXN2030 is one of 42 small molecule programs targeting Antibody-mediated Rejection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antibody-Mediated RejectionActive, not recruiting

ImmunogenicityActive, not recruiting

Antibody-Mediated RejectionPhase 2

Active, not recruiting

ImmunogenicityPhase 1

Active, not recruiting

Competition

Competitive Landscape

98 competitors in Immunogenicity

#DrugCompanyPhaseTrials

Perjeta

Roche

Phase 3

2 2

Rabies Vaccine

Novartis

Phase 3

12 3

Prolia

OOrganon and Co

Phase 3

2 4

Rsvpref

Pfizer

Phase 3

5 5

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

3 6

PCV21

Sanofi

Phase 3

2 7

Bexsero

GSK

Phase 3

8 8

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

2 9

Opfolda

Johnson & Johnson

Phase 3

1 10

Gardasil

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Immunogenicity

NCT05501717

Q4 2028

Phase 2Active, not recruiting

Antibody-Mediated Rejection

NCT06744647

Clinical

Trials by Indication[1]

Immunogenicity1 trial

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT05501717·48 enrolled

Antibody-mediated Rejection1 trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06744647·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALXN2030. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALXN2030 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALXN2030. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

ALXN2030

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Immunogenicity1 trial

Antibody-mediated Rejection1 trial

References

Drug Info

Quick Facts

Related News